Literature DB >> 1286062

Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures.

M T Bejarano1, R de Waal Malefyt, J S Abrams, M Bigler, R Bacchetta, J E de Vries, M G Roncarolo.   

Abstract

The effects of IL-10 on the generation of alloreactivity in primary mixed lymphocyte cultures (MLCs) were investigated. IL-10 inhibited in a dose-dependent fashion the alloantigen-induced proliferative responses. The suppressive effect was maximal when IL-10 was added at the beginning of the cultures, suggesting that it acts on the early stages of T cell activation. The proliferative responses were enhanced in the presence of a neutralizing anti-IL-10 mAb, indicating that endogenously produced IL-10 suppresses proliferation in primary MLC. The inhibitory effects of IL-10 were observed irrespective of whether irradiated allogeneic peripheral blood mononuclear cells, purified monocytes or freshly isolated B cells were used as stimulator cells. The proliferation of both the CD4+ and CD8+ T cell subsets was inhibited to a similar extent. The reduced proliferative responses were only minimally restored by high concentrations of exogenous IL-2, indicating that the effects of IL-10 are not exclusively due to inhibition of IL-2 synthesis. Furthermore, the production of IL-2, interferon (IFN)-gamma, IL-6, granulocyte macrophage colony stimulating factor, and tumor necrosis factor-alpha in primary MLCs was diminished by IL-10 and enhanced in the presence of anti-IL-10 mAb. The strongest effects were observed on the production of IFN-gamma. Although IL-10 reduces the proliferative responses, the ratios of CD3+CD4+ and CD3+CD8+ T cells remained the same in IL-10 treated and control cultures, yet the percentages of activated CD3+ T cells, as judged by CD25 and HLA-DR expression, were consistently reduced.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1286062     DOI: 10.1093/intimm/4.12.1389

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  23 in total

Review 1.  Recent advances in immunobiology of brain tumors.

Authors:  M Tada; N de Tribolet
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

2.  DSHP: a "power bar" for sustained immune responses?

Authors:  A B Satterthwaite; D J Rawlings; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

Review 3.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

4.  Identical genetic control of MLC reactivity to different MHC incompatibilities, independent of production of and response to IL-2.

Authors:  V Holán; M Lipoldová; P Demant
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

5.  Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production.

Authors:  D Schols; E De Clercq
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome.

Authors:  N Van Damme; F De Keyser; P Demetter; D Baeten; H Mielants; G Verbruggen; C Cuvelier; E M Veys; M De Vos
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

7.  Increased interleukin-10 production and Th2 skewing in the absence of 5-lipoxygenase.

Authors:  Daniel DiMeo; Jun Tian; Juan Zhang; Seiko Narushima; Daniel J Berg
Journal:  Immunology       Date:  2007-09-25       Impact factor: 7.397

8.  Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.

Authors:  L Gorelik; A Prokhorova; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

9.  High-level IL-10 production by monoclonal antibody-stimulated human T cells.

Authors:  M Schwarz; O Majdic; W Knapp; W Holter
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

10.  Involvement of interleukin-4 and -10 in inflammatory bowel disease.

Authors:  O H Nielsen; T Køppen; N Rüdiger; T Horn; J Eriksen; I Kirman
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.